NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Fasciculation


Return to Library

Free Fasciculation Articles


Studies from Jikei University, Department of Psychiatry provide new data on life sciences



2009 JUN 1 - (NewsRx.com) -- New research, 'Effect of distigmine bromide on the central cholinergic system,' is the subject of a report. According to a study from Tokyo, Japan, "Distigmine bromide (3, 3'-[hexamethylenebis (methyliminocarbonyloxy)] bis (1-methylpyridinium) dibromide), an acetylcholinesterase (AChE) inhibitor, produced a time-dependent and dose-dependent increase in acetylcholine (ACh) levels in the medial prefrontal cortex of rats. The overt cholinergic behaviours, such as tremor, fasciculation and lacrimation, were also elicited by distigmine bromide."

"The onset and duration of these behaviours were reflected in the microdialysis data showing that distigmine bromide enhances cholinergic neurotransmission in rat brain. The dose of distigmine bromide eliciting increase in ACh in the medial prefrontal cortex of rats correlated well with its dose for the induction of the cholinergic behaviours. Furthermore, distigmine bromide was an equipotent inhibitor of AChE and butyrylcholinesterase (BuChE) activities in the present study," wrote K. Nakayama and colleagues, Jikei University, Department of Psychiatry.

The researchers concluded: "From these findings, it is suggested that distigmine bromide may produce centrally mediated behavioural signs by increasing the ACh levels in the brain, resulting from its AChE and BuChE inhibitions."

Nakayama and colleagues published the results of their research in the Journal of Psychopharmacology (Effect of distigmine bromide on the central cholinergic system. Journal of Psychopharmacology, 2009;23(2):190-3).

For additional information, contact K. Nakayama, Jikei University School of Medicine, Dept. of Psychiatry, Minato-ku, Tokyo, Japan.

The publisher of the Journal of Psychopharmacology can be contacted at: SAGE Publications, USA , 2455 Teller Road, Thousand Oaks, CA 91320, USA.

Keywords: Japan, Tokyo, Life Sciences, Fasciculation, Enzyme Research, Acetylcholinesterase, Microdialysis, Microtechnology, Psychopharmacology, Pharmacology, Psychiatry, Dialysis, Pharmaceuticals.

This article was prepared by Proteomics Weekly editors from staff and other reports. Copyright 2009, Proteomics Weekly via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login